Healthcare - Biotechnology - NASDAQ - US
$ 24.41
-2.05 %
$ 1.19 B
Market Cap
-13.05
P/E
INCOME STATEMENT
0
REVENUE
-83.5 M
OPERATING INCOME
-71.6 M
NET INCOME
EFFICIENCY
Earnings Waterfall
Enliven Therapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 297 K |
| Gross Profit | -297 K |
| Operating Expenses | 83.5 M |
| Operating Income | -83.5 M |
| Other Expenses | -11.9 M |
| Net Income | -71.6 M |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GROSS PROFIT | |||||||
| Cost Of Revenue | 0.3 | 0.6 | 99 K | 97 K | 33 K | 0 | 0 |
| Gross Profit | (0.3) | (0.6) | 99 K | 97 K | 33 K | 0 | 0 |
| OPERATING INCOME | |||||||
| Operating Expenses | 83.5 | 38.8 | 24.8 | 9.3 | 24.1 | 10.7 | 8.9 |
| Selling, General and Administrative Expenses | 19.0 | 7.8 | 4.3 | 1.1 | 5.1 | 2.4 | 1.0 |
| Research and Development Expenses | 64.6 | 31.0 | 20.5 | 8.2 | 19.0 | 8.2 | 7.9 |
| Operating Income | (83.5) | (38.8) | (24.8) | (9.3) | (24.1) | (10.7) | (8.9) |
| PRE-TAX INCOME | |||||||
| Interest Income Expense | 0 | (1.2) | 0 | 0 | 0 | 0 | 0 |
| Total Other Income | 11.9 | 1.1 | 22 K | (9.6) | 0.7 | (0.7) | 9.1 |
| Pre-Tax Income | (71.6) | (37.7) | (24.7) | (19.0) | (23.5) | (11.3) | 0.2 |
| NET INCOME | |||||||
| Tax Provision | 0 | 88 K | 22 K | 31 K | 0.7 | (0.8) | 0.2 |
| Net Income | (71.6) | (37.8) | (24.7) | (18.9) | (23.5) | (11.3) | 0 |
| EPS | 2.01 | 12.1 | 10.7 | 5.44 | 5.43 | 2.62 | 0 |